AIA Group Ltd Boosts Holdings in Bristol-Myers Squibb (NYSE:BMY)

AIA Group Ltd boosted its position in Bristol-Myers Squibb (NYSE:BMY) by 15.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 55,976 shares of the biopharmaceutical company’s stock after purchasing an additional 7,290 shares during the quarter. AIA Group Ltd’s holdings in Bristol-Myers Squibb were worth $2,872,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of BMY. Norges Bank purchased a new position in Bristol-Myers Squibb during the fourth quarter worth about $1,873,696,000. Northern Trust Corp boosted its position in shares of Bristol-Myers Squibb by 5.8% during the 3rd quarter. Northern Trust Corp now owns 25,292,711 shares of the biopharmaceutical company’s stock valued at $1,467,989,000 after acquiring an additional 1,394,158 shares during the last quarter. Moneta Group Investment Advisors LLC grew its holdings in shares of Bristol-Myers Squibb by 114,228.7% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 21,469,785 shares of the biopharmaceutical company’s stock worth $1,544,751,000 after purchasing an additional 21,451,006 shares in the last quarter. Invesco Ltd. raised its stake in Bristol-Myers Squibb by 8.6% in the third quarter. Invesco Ltd. now owns 15,606,587 shares of the biopharmaceutical company’s stock valued at $905,806,000 after purchasing an additional 1,240,902 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Bristol-Myers Squibb by 1.8% during the first quarter. Charles Schwab Investment Management Inc. now owns 11,005,473 shares of the biopharmaceutical company’s stock valued at $803,730,000 after purchasing an additional 197,000 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

BMY has been the topic of a number of research analyst reports. Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Bank of America cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their target price for the company from $68.00 to $60.00 in a research note on Wednesday, January 3rd. Redburn Atlantic lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $77.00 to $54.00 in a research note on Tuesday, February 6th. Wells Fargo & Company increased their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research report on Thursday. Finally, StockNews.com downgraded Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Monday. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Bristol-Myers Squibb currently has an average rating of “Hold” and a consensus price target of $61.18.

Bristol-Myers Squibb Stock Performance

Shares of NYSE BMY traded up $0.39 during trading on Thursday, reaching $48.23. 7,132,429 shares of the company traded hands, compared to its average volume of 15,729,137. The firm has a 50 day simple moving average of $51.26 and a 200-day simple moving average of $51.59. Bristol-Myers Squibb has a 52-week low of $47.58 and a 52-week high of $70.93. The stock has a market capitalization of $97.75 billion, a PE ratio of 12.46, a P/E/G ratio of 1.49 and a beta of 0.39. The company has a quick ratio of 1.31, a current ratio of 1.43 and a debt-to-equity ratio of 1.24.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.55 by $0.15. The company had revenue of $11.48 billion for the quarter, compared to analysts’ expectations of $11.19 billion. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The firm’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter last year, the company posted $1.82 earnings per share. Equities research analysts anticipate that Bristol-Myers Squibb will post 6.47 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 4.98%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is 62.18%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.